

Literaturverzeichnis

Hamburger Ärzteblatt 07/8 | 2017

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12-16: Frühdiagnostik von Parkinson. *Von Prof. Dr. Daniela Berg*

1. Parkinson J. An Essay on the shaking palsy. Writtingham and Rowland, London, 1817.
2. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). *J Neurol.* 2002 Oct;249 Suppl 3:III/1-5. Review.
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain.* 1991 Oct;114 (Pt 5):2283-301.
4. Gonera EG, van't Hof M, Berger HJ, van Weel C, Horstink MW. Symptoms and duration of the prodromal phase in Parkinson's disease. *Mov Disord.* 1997 Nov;12(6):871-6.
5. Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of α -synuclein pathology. *Neuropathol Appl Neurobiol.* 2016 Feb;42(1):33-50
6. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson's disease. *Mov Disord.* 2016 Aug;31(8):1114-9.
7. Dunning CJ, George S, Brundin P. What's to like about the prion-like hypothesis for the spreading of aggregated α -synuclein in Parkinson disease? *Prion.* 2013 Jan-Feb;7(1):92-7.
8. Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. *Nat Rev Neurol.* 2016 Oct 27;12(11):622-634.
9. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson's disease. *Mov Disord.* 2015 Oct;30(12):1600-11.
10. Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlke P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srujijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. *Mov Disord.* 2013 Feb;28(2):216-9.
11. Fereshtehnejad SM, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB. Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. *Mov Disord.* 2017 Apr 21. doi: 10.1002/mds.26989. [Epub ahead of print]
12. Pilotto, S. Heinzl, U. Suenkel, S. Lerche, K. Brockmann, B. Roeben, E. Schaeffer, I. Wurster, R. Yilmaz, I. Liepelt-Scarfone, A.-K. von Thaler, F.G. Metzger, G.W. Eschweiler, R.B. Postuma, W. Maetzler, D. Berg. Application of the MDS prodromal research criteria in two independent prospective cohorts. *Mov Disord*, accepted
13. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson's disease. *Mov Disord.* 2015 Oct;30(12):1600-11.
14. Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, Oertel W, Ju YE, Puligheddu M, Jennum P, Pelletier A, Wolfson C, Leu-Semenescu S, Frauscher B, Miyamoto M, Cochen De Cock V, Unger MM, Stiasny-Kolster K, Fantini ML, Montplaisir JY. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. *Mov Disord.* 2012 Jun;27(7):913-6.

Literaturverzeichnis

Hamburger Ärzteblatt 07/8 | 2017

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 28-29: Kardiale Toxizität onkologischer Therapien. *Von Prof. Dr. Andreas van de Loo, Prof. Dr. Udo Vanhoefler*

1. Zamorano JL et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines Eur Heart J 2016;37:2768-2801.
2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879.
3. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomo G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-220.
4. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.
5. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493-498.
6. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63(25 Pt A):2751-2768.
7. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:1-10.
8. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-1093.
9. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-522.
10. Thakur A, Witteles RM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail 2014;20:155-158.
11. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;15:47.

Literaturverzeichnis

Hamburger Ärzteblatt 07/8 | 2017

Seite 3

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

12. Larsen TB, Nielsen PB, Skjoth F, Rasmussen LH, Lip GY. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014;9:e114445.

S. 30-31: Entspannter Bauch dank Botox. *Von Oliver Stern, Dr. Thomas Mansfeld*

1. Deerenberg EB, Timmermans L, Hogerzeil DP et al. A systematic review of the surgical treatment of large incisional hernia. Hernia 2015;19:89–101. doi:10.1007/s10029-014-1321-x.
2. Helgstrand F, Rosenberg J, Kehlet H, Jørgensen LN, Bisgaard T. Nationwide prospective study of outcome after elective incisional hernia repair. J Am Coll Surg 2012;216:217–228. doi: 10.1016.
3. Helgstrand F, Rosenberg J, Kehlet H, Strandfelt P, Bisgaard T. Reoperation vs. clinical recurrence rate after ventral hernia repair. Ann Surg 2012;256:955–958. doi:10.1097/SLA.0b013e 318254f5b9.
4. Zendejas B, Khasawneh MA, Srvantstyan B et al. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg 2013;37:2830–2837. doi:10.1007/s00268-013-2211-6.
5. Ibarra-Hurtado TR, Nuno-Guzman CM, Miranda-Diaz AG et al. Effect of botulinum toxin type A in lateral abdominal wall muscles thickness and length of patients with midline incisional hernia secondary to open abdomen management. Hernia 2014;18:647–652. doi:10.1007/s10029-014-1280-2.
6. Smoot D, Zielinski M, Jenkins D, Schiller H. Botox A injection for pain after laparoscopic ventral hernia: a case report. Pain Med. 2011;12:1121–3. 11. Zielinski MD.
7. Dressler D. Clinical applications of botulinum toxin. Curr. Opin. Microbiol. 2012;15: 325–36.
8. Köhler, G. et al. „Die Komponentenseparation zum Verschluss komplexer Bauchwandhernien: Entwicklung einer Technik von 1990 bis heute.“ Zentralblatt für Chirurgie-Zeitschrift für Allgemeine, Viszeral-, Thorax-und Gefäßchirurgie 140.02. 2015;186-192.

S. 34-35: Zwischen Stigma und Idealisierung.

Von Anne Deborah Scholz-Hehn, Dr. Jana Christina Müller, Dr. Heiko Albrecht, Dr. Daniel Luedecke, Dr. Juliane Schulze-Thüsing, Dr. Laura Stumm, Prof. Klaus Wiedemann, Prof. Jürgen Gallinat, Dr. Nils Freundlieb

1. Bundesärztekammer. Stellungnahme zur Elektrokrampftherapie (EKT) als psychiatrische Behandlungsmaßnahme. Dtsch. Arztebl. 3. 2003;141–143.
2. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg.) für die Leitliniengruppe Unipolare Depression, D. S3-Leitlinie/ Nationale VersorgungsLeitlinie Unipolare Depression.
3. DGBS e.V. und DGPPN e.V. S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.0. 2012.
4. Zilles D, Wolff-Menzler, C & Wiltfang J. Elektrokrampftherapie zur Behandlung unipolar depressiver Störungen. Nervenarzt 86. 2014;549–556 2014.
5. Wang W et al. Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis. Shanghai Arch. psychiatry 27. 2015;206–19.

Literaturverzeichnis

Hamburger Ärzteblatt 07/8 | 2017

Seite 4

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

6. Rzesnitzek L & Lang S. 'Electroshock Therapy' in the Third Reich. *Med. Hist.* 61. 2017;66–88.
7. Hoffmann-Richter U., Alder B & Finzen A. Die Elektrokrampftherapie und die Defibrillation in der Zeitung. Eine Medienanalyse. *Nervenarzt* 69. 1998;622–628.
8. Matthews AM, Rosenquist PB & McCall, WV Representations of ECT in English-Language Film and Television in the New Millennium. *J. ECT* 0. 2016;1–5.
9. Rose DS, Wykes TH, Bindman JP & Fleischmann PS. Information, consent and perceived coercion: Patients' perspectives on electroconvulsive therapy. *Br. J. Psychiatry* 186. 2005;54–59.
10. Fink M. Bearing Witness. *J ECT* 32. 2016,13–6.
11. Tess AV & Smetana GW. Medical evaluation of patients undergoing electroconvulsive therapy. *N. Engl. J. Med.* 360. 2009;1437–1444.
12. Jelovac A, Kolshus E & McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. *Neuropsychopharmacology* 38. 2013;2467–74.
13. Kellner CH. Relapse after electroconvulsive therapy (ECT). *J. ECT* 29. 2013;1–2.
14. Brakemeier EL et al. Cognitive-Behavioral Therapy as Continuation Treatment to Sustain Response After Electroconvulsive Therapy in Depression: A Randomized Controlled Trial. *Biol. Psychiatry* 76. 2013;194–202.
15. Kellner CH et al. A novel strategy for continuation ect in geriatric depression: Phase 2 of the pride study. *Am. J. Psychiatry* 173. 2016;1110–1118.